Live Breaking News & Updates on Condensed Financial|Page 11
Stay updated with breaking news from Condensed financial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1st Capital Bank: 1st Capital Bancorp Announces Fourth Quarter 2020 Financial Results SALINAS, CA / ACCESSWIRE / January 29, 2021 / 1st Capital Bancorp (OTC PINK:FISB) reported unaudited net income of $1.59 million for the three months ended December 31, 2020, an increase of 67.1% compared to net income of $953 thousand in the third quarter of 2020 and a decrease of 8.1% compared to net income of $1.73 million in the fourth quarter of 2019. Earnings per share were $0.28 (diluted) for the fourth quarter of 2020, compared to $0.17 (diluted) for the prior quarter, and $0.31 (diluted) for the fourth quarter of 2019. Unaudited net income for the year ended December 31, 2020 was $4.50 million, a decrease of 36.5% compared to net income of $7.09 million for the year ended December 31, 2019. Year-to-date earnings per share were $0.81 (diluted) and $1.27 (diluted) for the years ended December 31, 2020 and 2019, respectively. ....
13 1Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions. 2Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 3 Please see detailed guidance assumptions on page 8 including the forecast assumption that we see a continuation of the return to normal global healthcare systems including prescription dynamics by mid 2021. In addition, we assume that no Gilenyaand noSandostatinLAR generics enter in 2021 in the US. ....
Novartis International AG: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020. Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Cosentyx (+13% cc), Xiidra acquisition (+95% cc) Promacta/Revolade (+23% cc), Piqray (reaching USD 0.3 billion) Sandoz sales were in line (cc, -1% USD), with Biopharmaceuticals growing 19% (cc) COVID-19 negatively impacted demand, particularly: ophthalmology, dermatology and Sandoz retail Core operating income² grew 13% (cc, +9% USD) and Innovative Medicines and Sandoz core margin improved to 35% and 24% of sales respectively, driven by sales growth, lower spend and productivity Continued transformation of Manufacturing and Business Services contributing to core margin expansion ....